Microphthalmia transcription factor (MiT) family translocation renal cell carcinomas (TRCC) are rare subtypes of kidney cancers, which often arise in children and young adults. TRCC are characterized by translocations affecting transcription factors: Transcription Factor Binding To Immunoglobulin Heavy Constant Mu Enhancer 3 (TFE3) and Transcription Factor EB (TFEB). Little is known about TRCC molecular heterogeneity, in particular their transcriptomic and epigenetic subtype classification. Clinical behavior of TRCC is varying with age and Tumor, Node, Metastasis (TNM) stage. However, the biological basis of this aggressiveness is poorly understood. PURPOSE: The primary goal of this study is to decipher specific alterations in aggressive TRCC, defined as cases with metastatic dissemination at diagnosis. To tackle this problem, a retrospective cohort of TRCC cases in children and young adults will be created. We will then perform integrative comprehensive multi-omics analysis of these tumors to identify genetic, epigenetic and immune biomarkers associated with metastatic behavior in a training and validation datasets. Comparison of the multi-omics data will be compared to other type of rare Kidney tumors as well as clear-cell renal cell carcinomas
This retrospective cohort study aims to allow tumor collection of TRCC from three different networks: the French research network in renal cancer (UroCCR), the International Society of Paediatric Oncology (SIOP) database and the network for rare renal carcinomas (CARARE). Those samples will be divided in training and validation datasets. We will also collect samples from patients with other rare kidney cancers and clear-cell renal cell carcinomas allowing comparisons of similarity and differences between these tumors.
Study Type
OBSERVATIONAL
Enrollment
600
Retrospective data collection
Réseau Français de Recherche sur le Cancer du Rein (UroCCR)
Bordeaux, France
Réseau SIOP, Hôpital Trousseau
Paris, France
Réseau CARARE
Rennes, France
Institut de cancérologie Strasbourg Europe
Strasbourg, France
Identification of genetic alterations associated with TRCC aggressiveness.
Tumor aggressiveness is defined as TRCC cases with metastatic dissemination at diagnosis. Comparison of recurrent genetic aberration identified between metastatic and localized cases.
Time frame: at the end of the study (36 months)
Progression free survival (PFS)
Testing for association between molecular tumor features and clinico-pathological patients outcome, PFS, according to the identity of TFE fusion partner
Time frame: From renal tumor diagnosis to progression or latest patient news at the end of the study (36 months)
Overall survival (OS)
Testing for association between molecular tumor features and clinico-pathological patients outcome, OS, according to the identity of TFE fusion partner
Time frame: From renal tumor diagnosis to death or latest patient news at the end of the study (36 months)6 months)
Contribution of DNA methylation, transcriptome and immune landscape to metastatic potential
Proportion of patients with metastatic disease in each DNA methylation and messenger RNA (mRNA) cluster using hierarchical unsupervised subtype classifications
Time frame: at the end of the study (36 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.